Argo Biopharma has named Gena Wang, PhD, CFA, its new Chief Financial Officer (CFO) and Chief Strategy Officer (CSO). The appointments took effect March 1, 2026.

Wang Background and Experience

Wang was previously Managing Director and senior equity research analyst in the biotechnology sector at Barclays. Argo, a clinical-stage biotech developing next-generation small interfering RNA (siRNA) therapies, says Wang’s forte is in-depth research on novel therapies.

While this research includes RNA, cell and gene, and emerging modalities, Wang also has 20-plus years Wall Street sell-side experience. She is further recognized for her work in rare diseases and oncology.

“I am thrilled to join Argo Biopharma at such an important stage of its development,” Wang said.

She added that she has followed the evolution of RNA therapies for decades.

“I believe Argo has developed a compelling, innovative siRNA platform to support potentially differentiated best-in-class assets,” Wang said. “I look forward to partnering with the management team to help Argo Biopharma achieve its long-term goals.”

These goals, she said, include “delivering transformative therapeutics to patients while creating value for shareholders.”

Goals for New Argo CFO/CSO

On those goals, Dongxu Shu, PhD, co-founder, Chairman of the Board, and CEO of Argo Biopharma, concurs.

Shu touted Wang’s “deep knowledge of the genetic medicines landscape” and “expertise in biotechnology capital markets.”

Furthermore, Shu said, Wang’s “reputation and strong relationships within the financial community and healthcare industry make her an invaluable addition.”

“We are excited to welcome Dr. Wang to our management team,” Shu said. “We [will] continue advancing our pipeline and entering our next phase of growth. I look forward to working closely with Dr. Wang in her new role.”